Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.

The monoclonal antibody, cetuximab, binds to epidermal growth-factor receptor and thus provides an opportunity to create both imaging and therapies that target this receptor. The potential of cetuximab as a radioimmunoconjugate, using the acyclic bifunctional chelator, CHX-A"-DTPA, was investigated. The pharmacokinetic behavior in the blood was determined in mice with and without tumors. Tumor targeting and scintigraphic imaging were evaluated in mice bearing xenografts of LS-174T (colorectal), SHAW (pancreatic), SKOV3 (ovarian), DU145 (prostate), and HT-29 (colorectal). Excellent tumor targeting was observed in each of the models with peak tumor uptakes of 59.8 +/- 18.1, 22.5 +/- 4.7, 33.3 +/- 5.7, 18.2 +/- 7.8, and 41.7 +/- 10.8 injected dose per gram (%ID/g) at 48-72 hours, respectively. In contrast, the highest tumor %ID/g obtained in mice bearing melanoma (A375) xenografts was 6.3 +/- 1.1 at 72 hours. The biodistribution of (111)In-cetuximab was also evaluated in nontumor-bearing mice. The highest %ID/g was observed in the liver (9.3 +/- 1.3 at 24 hours) and the salivary glands (8.1 +/- 2.8 at 72 hours). Scintigraphy showed excellent tumor targeting at 24 hours. Blood pool was evident, as expected, but cleared over time. At 168 hours, the tumor was clearly discernible with negligible background.

[1]  Vladimir Tolmachev,et al.  Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  M. Brechbiel,et al.  Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent , 2009, British journal of pharmacology.

[3]  D. A. Capretto,et al.  Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. , 2008, Cancer biotherapy & radiopharmaceuticals.

[4]  W. Cai,et al.  Non-Invasive PET Imaging of EGFR Degradation Induced by a Heat Shock Protein 90 Inhibitor , 2008, Molecular Imaging and Biology.

[5]  Tristan Barrett,et al.  In vivo Diagnosis of Epidermal Growth Factor Receptor Expression using Molecular Imaging with a Cocktail of Optically Labeled Monoclonal Antibodies , 2007, Clinical Cancer Research.

[6]  Dongsheng Tu,et al.  Cetuximab for the treatment of colorectal cancer. , 2007, The New England journal of medicine.

[7]  P. Choyke,et al.  Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. , 2007, Journal of medicinal chemistry.

[8]  F. Ciardiello,et al.  Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer , 2007, Oncogene.

[9]  P. Keegan,et al.  FDA drug approval summary: panitumumab (Vectibix). , 2007, The oncologist.

[10]  M. Saif,et al.  Panitumumab the first fully human monoclonal antibody: from the bench to the clinic , 2007, Anti-cancer drugs.

[11]  B D Kahan,et al.  Human colonic adenocarcinoma cells , 1976, In Vitro.

[12]  A. Koong,et al.  Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  R. Tarnawski,et al.  Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors. , 2006, Hybridoma.

[14]  F. Luo,et al.  Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels , 2006, Molecular Cancer Therapeutics.

[15]  Z. Hua.  Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .

[16]  C. R. Leemans,et al.  (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  M. Brechbiel,et al.  Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. , 2005, Cancer biotherapy & radiopharmaceuticals.

[18]  M. Decamp,et al.  The Role of Surgery in N2 Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[19]  F. Lee,et al.  Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft , 2005, Cancer Chemotherapy and Pharmacology.

[20]  R. Figueredo,et al.  Local and systemic toxicity of h-R3, an anti-epidermal growth factor receptor monoclonal antibody, labeled with 188osmiun after the intracerebral administration in rats. , 2005, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[21]  B. Burtness,et al.  Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. , 2005, Drugs of today.

[22]  T. Yokota,et al.  Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant , 2005, Cancer Immunology, Immunotherapy.

[23]  L. Ellis,et al.  Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  P M Harari,et al.  Epidermal growth factor receptor inhibition strategies in oncology. , 2004, Endocrine-related cancer.

[25]  David J. Yang,et al.  Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  David J. Yang,et al.  Assessment of epidermal growth factor receptor with 99mTc–ethylenedicysteine–C225 monoclonal antibody , 2003, Anti-cancer drugs.

[27]  Roy S Herbst,et al.  Monoclonal antibodies to target epidermal growth factor receptor–positive tumors , 2002, Cancer.

[28]  Edward S. Kim,et al.  Epidermal growth factor receptor biology (IMC-C225) , 2001, Current opinion in oncology.

[29]  Chun Xing Li,et al.  Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  J. Baselga.  The EGFR as a target for anticancer therapy--focus on cetuximab. , 2001, European journal of cancer.

[31]  Chun Xing Li,et al.  Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains. , 2001, Bioconjugate chemistry.

[32]  I. Pastan,et al.  Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides. , 2001, Nuclear medicine and biology.

[33]  G. Snow,et al.  Perspectives of combined radioimmunotherapy and anti‐EGFR antibody therapy for the treatment of residual head and neck cancer , 1998, International journal of cancer.

[34]  I. Pastan,et al.  Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. , 1997, Bioorganic & medicinal chemistry.

[35]  P. Hand,et al.  Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. , 1995, Cancer research.

[36]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[37]  I. Pastan,et al.  Preclinical evaluation of 111In-labeled B3 monoclonal antibody: biodistribution and imaging studies in nude mice bearing human epidermoid carcinoma xenografts. , 1993, Cancer research.

[38]  M. Brechbiel,et al.  Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. , 1992, Bioconjugate chemistry.

[39]  D. E. Simpson,et al.  New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  P. Hand,et al.  Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein. , 1985, Cancer research.

[41]  S. Singer,et al.  Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[42]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[43]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.